SCHEMBL6495220

SCHEMBL6495220

COC(=O)N1CCC(O)CC1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EPHX1 P07099 1/20 0.45
NPC1 O15118 1/20 0.45
RAB9A P51151 1/20 0.45
CHRNB2 P17787 2/20 0.44
CHRNA4 P43681 2/20 0.44
CHRNB4 P30926 1/20 0.44
CHRNA3 P32297 1/20 0.44
BRD4 O60885 2/20 0.43
BRDT Q58F21 1/20 0.43
L3MBTL1 Q9Y468 2/20 0.41
USP2 O75604 1/20 0.41
CYP1A2 P05177 1/20 0.41
CYP2C9 P11712 1/20 0.41
THRB P10828 1/20 0.41
ATM Q13315 1/20 0.41
GRM3 Q14832 1/20 0.41
TSHR P16473 1/20 0.40
GAA P10253 1/20 0.40
CYP2D6 P10635 1/20 0.40
ALDH1A1 P00352 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6484170 0.87 CHRNB2 (0.46) EPHX1CHRNB2CHRNA4CHRNB4CHRNA3
SCHEMBL3854429 0.87 CHRNB2 (0.46) EPHX1CHRNB2CHRNA4CHRNB4CHRNA3
SCHEMBL1942044 0.87 CHRNB2 (0.46) EPHX1CHRNB2CHRNA4CHRNB4CHRNA3
SCHEMBL20993453 0.82 EPHX1 (0.45) EPHX1CHRNB2CHRNA4CHRNB4CHRNA3
SCHEMBL29589464 0.82 EPHX1 (0.45) EPHX1CHRNB2CHRNA4CHRNB4CHRNA3
SCHEMBL771850 0.82 GAA (0.53) EPHX1NPC1CHRNB2CHRNA4CHRNB4
SCHEMBL13907560 0.80 USP2 (0.45) EPHX1USP2CYP1A2CYP2C9TSHR
SCHEMBL18697087 0.80 EPHX1 (0.44) EPHX1CHRNB2CHRNA4CHRNB4CHRNA3
SCHEMBL12321755 0.80 EPHX1 (0.44) EPHX1NPC1RAB9ACHRNB2CHRNA4
Hydrochloric Acid SCHEMBL12494569 0.80 GAA (0.51) EPHX1NPC1CHRNB2CHRNA4CHRNB4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117106741-A Alcohol dehydrogenase mutant and application thereof 清华大学 2023-11-24 CN claimed
CN-114206893-A (hetero) aryl-methyl-thio-beta-D-galactopyranoside derivatives 爱杜西亚药品有限公司 2022-03-18 CN claimed
US-20250092009-A1 SUBSTITUTED CONDENSED THIOPHENES AS MODULATORS OF STING CTXT PTY LTD (AU) 2025-03-20 US disclosed
CN-112424181-B Substituted condensed thiophenes as STING modulators 希泰克斯特私人有限公司 2024-02-27 CN disclosed
CN-117106741-A Alcohol dehydrogenase mutant and application thereof 清华大学 2023-11-24 CN disclosed
EP-3793988-B1 SUBSTITUTED CONDENSED THIOPHENES AS MODULATORS OF STING CTXT PTY LTD (AU) 2023-11-15 EP disclosed
EP-3793988-B1 SUBSTITUTED CONDENSED THIOPHENES AS MODULATORS OF STING CTXT PTY LTD (AU) 2023-11-15 EP disclosed
CN-116669724-A T-type calcium channel modulators and methods of use thereof 普拉西斯精密医药公司 2023-08-29 CN disclosed
US-20230227423-A1 SUBSTITUTED CONDENSED THIOPHENES AS MODULATORS OF STING CTXT PTY LTD (AU) 2023-07-20 US disclosed
US-20230227423-A1 SUBSTITUTED CONDENSED THIOPHENES AS MODULATORS OF STING CTXT PTY LTD (AU) 2023-07-20 US disclosed
US-20230227423-A1 SUBSTITUTED CONDENSED THIOPHENES AS MODULATORS OF STING CTXT PTY LTD (AU) 2023-07-20 US disclosed
US-6969712-B2 Benzimidazole derivatives BANYU PHARMACEUTICAL CO., LTD. (JP) 2005-11-29 US disclosed
WO-2005105779-A1 3-HETEROCYCLYL-4-PHENYL-TRIAZOLE DERIVATIVES AS INHIBITORS OF THE VASOPRESSIN V1A RECEPTOR PFIZER LIMITED (GB) 2005-11-10 WO disclosed
US-20040044056-A1 Benzimidazole derivatives BANYU PHARMACEUTICAL CO., LTD. (JP) 2004-03-04 US disclosed
EP-0974602-B1 Catalyst and process for hydrogenating olefinically unsaturated compound JSR CORP (JP) 2004-01-02 EP disclosed
EP-1355882-A1 CHIRAL SCAFFOLDS AND THEIR PREPARATION Chirotech Technology Limited (GB) 2003-10-29 EP disclosed
EP-1342717-A1 BENZIMIDAZOLE DERIVATIVES BANYU PHARMACEUTICAL CO., LTD. (JP) 2003-09-10 EP disclosed
WO-2002053536-A1 CHIRAL SCAFFOLDS AND THEIR PREPARATION CHIROTECH TECHNOLOGY LTD. (GB) 2002-07-11 WO disclosed
US-6291596-B1 CONTACTING OLEFINICALLY UNSATURATED COMPOUND WITH HYDROGEN IN THE PRESENCE OF A HYDROGENATION CATALYST COMPRISING TITANIUM OR ZIRCONIUM OR HAFNIUM COMPOUND IN AN INERT, ORGANIC SOLVENT JSR CORPORATION (JP) 2001-09-18 US disclosed
EP-0974602-A1 Catalyst and process for hydrogenating olefinically unsaturated compound JSR Corporation (JP) 2000-01-26 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230227423-A1 SUBSTITUTED CONDENSED THIOPHENES AS MODULATORS OF STING STING1, CGAS, IRF3 EPHX1 865/4885NPC1 2168/4885RAB9A 1812/4885
US-20040044056-A1 Benzimidazole derivatives GPR119, OPRL1, INSR EPHX1 4704/4885NPC1 440/4885RAB9A 4502/4885
US-20250092009-A1 SUBSTITUTED CONDENSED THIOPHENES AS MODULATORS OF STING STING1, CGAS, IRF3 EPHX1 865/4885NPC1 2168/4885RAB9A 1812/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.